{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-012280","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.853408+00:00","generated_at":"2026-06-06T06:04:41.554743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Applied DNA Q1 revenue down 83% to $891K; operating loss widens to $3.8M","bullets":["Revenue $891K vs $5.3M YoY, down 83% due to COVID-19 testing decline (CUNY contract ended) and lower cotton DNA tagging revenue.","Operating loss $3.8M vs $1.2M YoY; Adjusted EBITDA negative $3.2M vs negative $1.1M.","Cash $3.4M at Dec 31 vs $7.2M at Sep 30; post-quarter closed $3.44M direct offering with warrants.","Company projects initial GMP facility capacity enabling up to $15M annual Linea IVT revenue, expected online H1 2024.","Clinical-stage mRNA customer evaluation: Linea IVT templates met/exceeded all metrics, fastest manufacturing speed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-012280","json":"https://secwatch.observer/filing/0001104659-24-012280.json","markdown":"https://secwatch.observer/filing/0001104659-24-012280.md","text":"https://secwatch.observer/filing/0001104659-24-012280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465924012280/0001104659-24-012280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465924012280/tm245568d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:04:41.554743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86dd526f5dc979f2b1264c705cf623656bc7e199","claim":"BNB PLUS CORP. reported the three-month period ended December 31, 2023 results: revenue approximately $891 thousand.","evidence_excerpt":"Total revenues were approximately $891 thousand for the three-month period December 31, 2023, compared to $5.3 million for the same period in the prior fiscal year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465924012280/0001104659-24-012280-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three-month period ended December 31, 2023"},{"label":"Revenue","value":"approximately $891 thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}